NDAORALTABLETPriority Review
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VASCOR (bepridil hydrochloride) is an oral calcium channel blocker approved in 1990 for angina pectoris management. It reduces myocardial oxygen demand and improves coronary blood flow in patients with chronic stable angina. The drug represents a legacy cardiovascular therapy in a mature therapeutic class.
LOE Approaching
With LOE approaching and no active expansion indications, this product likely operates with a lean commercial team focused on legacy portfolio management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VASCOR offers limited career growth opportunities given its LOE approaching status and zero linked job openings. Professionals joining this product should expect a focus on defensive portfolio management, cost containment, and margin optimization rather than strategic expansion or career acceleration.
Brand ManagerField Sales Representative
Worked on VASCOR at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.